Grow Medtech Recommends Early Proof of Market Studies for Successful Innovation

4 October 2021

Medipex collaborator, the Grow MedTech consortium of six Yorkshire Universities, has published a ground breaking guide to best practice for the assessment of early stage project market potential.

The guide explains how, by investing small amounts of money into proof of market awards, opportunities can be effectively de-risked under a “fail fast or prove it early” approach to safeguard precious time and money over the short and long term.

Medipex was a regular delivery partner for the market review studies and received excellent feedback throughout the scheme. The Grow MedTech team report, “For our proof of market awards scheme, we allocated £5k per award, expecting opinions from several key stakeholders (clinical and industrial), market analysis and also regulatory advice. The reports received have been of excellent quality. Clinical introductions have been effectively made leading to long term relationships. Regulatory advice has been found to be accurate and helpful and insight into markets has been of the standard expected and of high value to project teams.”

Medipex is able to offer similar reports to all our NHS, academic and industry clients to suit all budgets. To discuss how this approach can benefit your business please contact Agnes Crutchard, our Senior Market Intelligence Manager at enquiries@medipex.co.uk.